VBWG
Slides

Core Curriculum

• Impact of vascular biology in treatment of cardiovascular disease Section IV: Antithrombotic interventions in acute coronary syndromes

The VBWG Core Curriculum 2003 slide lecture compendium Impact of vascular biology in treatment of cardiovascular disease, provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.

Areas of focus:

The slides and accompanying notes in the 2002 VBWG core curriculum provided a broad overview of antithrombotic therapy. The 2003 program focuses on the interrelationship between antithrombotic therapy and catheterization in patients presenting with acute coronary syndromes (ACS). Another noteworthy feature of this year's program is a section on the adverse implications of diabetes in the patient with ACS.



03ACSA001.pdf (0.2MB)03ACSA001.pdf (0.2MB)

A. Epidemiology Update

Download 03ACSA001.ppt (2 slides - 0.4MB)

A.  Epidemiology Update Global variation in hospital management of ACS

B. Prothrombotic and antithrombotic pathways in the coronary vasculature

Download 03ACSB001.ppt (4 slides - 0.8MB)

B. Prothrombotic and antithrombotic pathways in the coronary vasculature Plaque rupture Thrombotic pathways Platelet activation

C-1. Clinical trial updates: Percutaneous coronary intervention

Download 03ACSC001.ppt (7 slides - 1.3MB)

C-1. Clinical trial updates: Percutaneous coronary intervention RITA 3: Evidence supporting early interventional strategy in UA/NSTEMI Model of in-stent restenosis In-stent restenosis rates RAVEL: 1-Year survival free of MI or repeat revascularization TAXUS I: Results at 6 and 12 months Primary PTCA vs thrombolysis in STEMI

C-2. Clinical trial updates: Direct thrombin inhibitors

Download 03ACSC002.ppt (3 slides - 0.6MB)

C-2. Clinical trial updates: Direct thrombin inhibitors Direct thrombin inhibitors in PCI: Peak-activated clotting time by dose REPLACE-2: Death, MI, urgent revascularization, major bleeding

C-3. Clinical trial updates: GP IIb/IIIa inhibitors

Download 03ACSC003.ppt (3 slides - 0.6MB)

C-3. Clinical trial updates: GP IIb/IIIa inhibitors GP IIb/IIIa inhibitors: Benefit related to revascularization strategy GP IIb/IIIa inhibitors: Events prevented and number-needed-to-treat

C-4. Clinical trial updates: Low-molecular-weight heparin

Download 03ACSC004.ppt (13 slides - 2.8MB)

C-4. Clinical trial updates: Low-molecular-weight heparin LMWH inhibits factor VIIa generation and prothrombin activation in vivo LMWH in PCI: Patients meeting anticoagulant goal at time of procedure Timecourse of anticoagulation with LMWH (enoxaparin) Evaluation of LMWH in high-risk UA/NSTEMI Anticoagulant efficacy in high-risk patients receiving LMWH Trials of LMWH plus GP Iib/IIIa inhibitors in PCI NRMI 3: LMWH/UFH plus GP Iib/IIIa inhibitors INTERACT: LMWH/UFH plus GP Iib/IIIa inhibitor in UA/NSTEMI INTERACT: LMWH/UFH plus GP Iib/IIIa inhibitor in non-ST-elevation ACS CRUISE: LMWH/UFH plus GP Iib/IIIa inhibitor in PCICRUISE: LMWH/UFH plus GP Iib/IIIa inhibitor in PCI (cont'd) Consensus algorithm for use of LMWH in PCI

D. Impact of Diabetes in ACS

Download 03ACSD001.ppt (7 slides - 1.3MB)

D. Impact of Diabetes in ACS Adverse impact of diabetes on survival following PCI ARTS: CABG vs stenting in patients with and without diabetes EPISTENT: GP IIb/IIIa inhibition reduces target vessel revascularization in diabetics undergoing stenting 1 in 3 NSTEMI patients: Culprit lesion not identified on angiography ACC/AHA guidelines for UA/NSTEMI: Revascularization in patients with diabetes ACC/AHA guidelines for UA/NSTEMI: Class I recommendations for antithrombotic therapy
corerefs.pdf (0.0MB)corerefs.pdf (0.0MB)
Published by Medical Education Consultants, Inc. (MEDCON), on behalf of the University of Florida College of Medicine.

The editorial content of this program does not necessarily reflect the views or recommendations of the University of Florida College of Medicine or AstraZeneca, Aventis Pharmaceuticals Inc, King Pharmaceuticals, Pfizer Inc, Wyeth Pharmaceuticals, or the publisher. The reader is advised to consult the full prescribing information of each product prior to use.

This program was prepared and produced by Medical Education Consultants, Inc, Westport, Connecticut, on behalf of the University of Florida College of Medicine through an unrestricted educational grant provided by AstraZeneca, Aventis Pharmaceuticals Inc, King Pharmaceuticals, Pfizer Inc, and Wyeth Pharmaceuticals.

©2003 Medical Education Consultants, Inc. (MEDCON). All rights reserved.

antithromboticbiologycardiovascularcompendiumcoronaryCurriculuminterventionssyndromesvascularVBWG

Related at vwbg.org

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section IV: Antithrombotic interventions in acute coronary syndromes

The VBWG Core Curriculum 2002 slide lecture program, Impact of vascular biology in treatment of cardiovascular disease, covers basic science and clinical advances in vascular biology in a spectrum of disorders.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section V: Atrial fibrillation, anticoagulation, and stroke prevention

The VBWG Core Curriculum 2003 slide lecture compendium Impact of vascular biology in treatment of cardiovascular disease , provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section III: Neurohormonal strategies in the failing heart

The VBWG Core Curriculum 2003 slide lecture compendium Impact of vascular biology in treatment of cardiovascular disease , provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.
More related